116 related articles for article (PubMed ID: 7928278)
1. The use of AMI-227 as an oral contrast agent for magnetic resonance imaging.
Rogers J; Lewis J; Josephson L
Invest Radiol; 1994 Jun; 29 Suppl 2():S81-2. PubMed ID: 7928278
[No Abstract] [Full Text] [Related]
2. Optimization of a negative oral contrast agent for magnetic resonance imaging.
Davis MA; Mei H; Ritsema GH
Invest Radiol; 1994 Jun; 29 Suppl 2():S120-2. PubMed ID: 7928205
[No Abstract] [Full Text] [Related]
3. Use of AMI-227 as an oral MR contrast agent.
Rogers J; Lewis J; Josephson L
Magn Reson Imaging; 1994; 12(4):631-9. PubMed ID: 8057768
[TBL] [Abstract][Full Text] [Related]
4. Superparamagnetic particles as an oral contrast agent in abdominal magnetic resonance imaging.
Oksendal AN; Jacobsen TF; Gundersen HG; Rinck PA; Rummeny E
Invest Radiol; 1991 Nov; 26 Suppl 1():S67-70; discussion S71. PubMed ID: 1808152
[No Abstract] [Full Text] [Related]
5. Comparison of iron oxide particles (AMI 227) with a gadolinium complex (Gd-DOTA) in dynamic susceptibility contrast MR imagings (FLASH and EPI) for both phantom and rat brain at 1.5 Tesla.
Loubeyre P; De Jaegere T; Bosmans H; Miao Y; Ni Y; Landuyt W; Marchal G
J Magn Reson Imaging; 1999 Mar; 9(3):447-53. PubMed ID: 10194716
[TBL] [Abstract][Full Text] [Related]
6. [Splenosis: value of MRI with injection of a superparamagnetic contrast agent].
Roussel A; Petit E; Mallet L; Zins M
J Radiol; 2008 Dec; 89(12):1944-6. PubMed ID: 19106854
[No Abstract] [Full Text] [Related]
7. A potentially artifact-free oral contrast agent for gastrointestinal MRI.
Liebig T; Stoupis C; Ros PR; Ballinger JR; Briggs RW
Magn Reson Med; 1993 Nov; 30(5):646-9. PubMed ID: 8259066
[TBL] [Abstract][Full Text] [Related]
8. Visualization of superior mesenteric lymph nodes by the combined oral and intravenous administration of the ultrasmall superparamagnetic iron oxide, AMI-227.
Rogers JM; Lewis J; Josephson L
Magn Reson Imaging; 1994; 12(8):1161-5. PubMed ID: 7854022
[TBL] [Abstract][Full Text] [Related]
9. Application of superparamagnetic iron oxide (AMI-227) for 3D phase-contrast MR angiography.
Tanimoto A; Yuasa Y; Hiramatsu K
Acad Radiol; 1998 Apr; 5 Suppl 1():S113-5. PubMed ID: 9561058
[No Abstract] [Full Text] [Related]
10. Vessel size imaging using low intravascular contrast agent concentrations.
Troprès I; Lamalle L; Farion R; Segebarth C; Rémy C
MAGMA; 2004 Dec; 17(3-6):313-6. PubMed ID: 15580376
[TBL] [Abstract][Full Text] [Related]
11. Comparative studies on the efficacy of MRI contrast agents in MRA.
Weinmann HJ; Bauer H; Ebert W; Frenzel T; Radüchel B; Platzek J; Schmitt-Willich H
Acad Radiol; 2002 May; 9 Suppl 1():S135-6. PubMed ID: 12019849
[No Abstract] [Full Text] [Related]
12. Biodistribution and toxicity of MR imaging contrast media.
Oksendal AN; Hals PA
J Magn Reson Imaging; 1993; 3(1):157-65. PubMed ID: 8428083
[No Abstract] [Full Text] [Related]
13. MR cholangiopancreatography diagnosis of juxtapapillary duodenal diverticulum simulating a cystic lesion of the pancreas: usefulness of an oral negative contrast agent.
Mazziotti S; Costa C; Ascenti G; Gaeta M; Pandolfo A; Blandino A
AJR Am J Roentgenol; 2005 Aug; 185(2):432-5. PubMed ID: 16037516
[No Abstract] [Full Text] [Related]
14. Imaging of macrophages in soft-tissue infection in rats: relationship between ultrasmall superparamagnetic iron oxide dose and MR signal characteristics.
Lutz AM; Weishaupt D; Persohn E; Goepfert K; Froehlich J; Sasse B; Gottschalk J; Marincek B; Kaim AH
Radiology; 2005 Mar; 234(3):765-75. PubMed ID: 15665219
[TBL] [Abstract][Full Text] [Related]
15. Phase III trial of oral magnetic particles in MRI of abdomen and pelvis.
MacVicar D; Jacobsen TF; Guy R; Husband JE
Clin Radiol; 1993 Mar; 47(3):183-8. PubMed ID: 8472481
[TBL] [Abstract][Full Text] [Related]
16. Contrast-enhanced magnetic resonance angiography in the coronary and peripheral arteries.
Saeed M; Wendland MF; Engelbrecht M; Sakuma H; Higgins CB
Acad Radiol; 1998 Apr; 5 Suppl 1():S108-12. PubMed ID: 9561057
[No Abstract] [Full Text] [Related]
17. Use of USPIO-induced magnetic susceptibility artifacts to identify sentinel lymph nodes and lymphatic drainage patterns. I. Dependence of artifact size with subcutaneous Combidex dose in rats.
Rogers JM; Jung CW; Lewis J; Groman EV
Magn Reson Imaging; 1998 Oct; 16(8):917-23. PubMed ID: 9814774
[TBL] [Abstract][Full Text] [Related]
18. Biodistribution of an ultrasmall superparamagnetic iron oxide colloid, BMS 180549, by different routes of administration.
Bengele HH; Palmacci S; Rogers J; Jung CW; Crenshaw J; Josephson L
Magn Reson Imaging; 1994; 12(3):433-42. PubMed ID: 8007773
[TBL] [Abstract][Full Text] [Related]
19. Optimization of an oral magnetic particle formulation as a gastrointestinal contrast agent for magnetic resonance imaging.
Rubin DL; Muller HH; Young SW; Hunke WA; Gorman WG
Invest Radiol; 1994 Jan; 29(1):81-6. PubMed ID: 8144343
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of liver-specific MRI contrast agents in rats with hepatitis and cirrhosis.
Kato N; Takahashi M; Ihara S; Tsujimoto T; Miyazawa T
Acad Radiol; 1998 Apr; 5 Suppl 1():S83-5. PubMed ID: 9561051
[No Abstract] [Full Text] [Related]
[Next] [New Search]
